Spots Global Cancer Trial Database for tumor infiltrating lymphocytes
Every month we try and update this database with for tumor infiltrating lymphocytes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer | NCT05524012 | Locally Advance... Neoadjuvant Tre... Radiotherapy Adaptive Treatm... | Blood sample MRI scan | 18 Years - | Jena University Hospital | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | NCT02383498 | Chordoma | Placebo GI-6301 Vaccine... Radiotherapy wGT3X-BT Actigr... | 18 Years - 100 Years | NantCell, Inc. | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | NCT02360579 | Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | NCT05645380 | Triple Negative... Breast Cancer | Carboplatin Docetaxel Doxorubicin Cyclophosphamid... Pembrolizumab | 18 Years - 70 Years | University of Kansas Medical Center | |
| ITIL-168 in Advanced Melanoma | NCT05050006 | Advanced Cutane... | ITIL-168 | 18 Years - | Instil Bio | |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | NCT03083873 | Squamous Cell C... | LN-145 LN-145-S1 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Triple-negative Breast Cancer: a New Perspective on Biomarkers | NCT03539965 | Triple Negative... Triple Negative... | 18 Years - 80 Years | Instituto Nacional de Cancer, Brazil | ||
| Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors | NCT05831033 | Solid Tumor | BEN101 | 18 Years - 70 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | NCT01585415 | Metastatic Canc... Melanoma | Vemurafenib Young TIL Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| A Clinical Study on TIL for the Treatment of Advanced Solid Tumors | NCT05087745 | Advanced Solid ... Tumor Infiltrat... Treatment Side ... Effects of Immu... | Tumor Infiltrat... | 18 Years - 75 Years | Shanghai Juncell Therapeutics | |
| Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | NCT02278887 | Metastatic Mela... | Translational r... Cyclophosphamid... Fludarabine Interleukin-2 Ipilimumab infu... | 18 Years - 75 Years | The Netherlands Cancer Institute | |
| Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | NCT02278887 | Metastatic Mela... | Translational r... Cyclophosphamid... Fludarabine Interleukin-2 Ipilimumab infu... | 18 Years - 75 Years | The Netherlands Cancer Institute | |
| ITIL-306 in Advanced Solid Tumors | NCT05397093 | Epithelial Ovar... Non-small Cell ... Renal Cell Carc... | ITIL-306 | 18 Years - | Instil Bio | |
| ITIL-168 in Advanced Solid Tumors | NCT05393635 | Cervical Cancer Head and Neck S... Non-small Cell ... | ITIL-168 | 18 Years - | Instil Bio | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| ITIL-168 in Advanced Melanoma | NCT05050006 | Advanced Cutane... | ITIL-168 | 18 Years - | Instil Bio | |
| Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | NCT00604136 | Metastatic Mela... | tumor infiltrat... | 18 Years - | Hadassah Medical Organization | |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | NCT04611126 | Metastatic Ovar... Metastatic Fall... Peritoneal Canc... | Ipilimumab Cyclophosphamid Fludarabine Pho... Tumor Infiltrat... Nivolumab Relatlimab | 18 Years - 75 Years | Herlev Hospital | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cellular Immunity and Renal Cell Cancer | NCT04377113 | NK Cell Mediate... NK Cell Cytokin... Kidney Cancer | 18 Years - | Clinical Hospital Center Rijeka | ||
| Study on TIL for the Treatment of Advanced Breast Cancer | NCT05142475 | Breast Cancer Treatment Side ... Advanced Breast... Effects of Immu... | Tumor Infiltrat... | 18 Years - 75 Years | Shanghai Juncell Therapeutics | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer | NCT05475847 | Cervical Cancer | Autologous Tumo... | 18 Years - 70 Years | Fudan University | |
| Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | NCT05645380 | Triple Negative... Breast Cancer | Carboplatin Docetaxel Doxorubicin Cyclophosphamid... Pembrolizumab | 18 Years - 70 Years | University of Kansas Medical Center | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin | NCT03960021 | Immune Evasion,... Neoplastic Cell... Circulating Tum... Pulmonary Metas... Colo-rectal Can... | RFA interventio... | 18 Years - | Institut Bergonié | |
| TIL Cells for the Treatment of the Advanced Solid Tumors Patients | NCT05649618 | Solid Tumor | Tumor Infiltrat... Fludarabine Cyclophosphamid... IL-2 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | NCT00604136 | Metastatic Mela... | tumor infiltrat... | 18 Years - | Hadassah Medical Organization | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) | NCT06120712 | Tumor Infiltrat... Safety Melanoma Efficacy Adverse Drug Ev... | GC101 TIL | 18 Years - 75 Years | Shanghai Juncell Therapeutics | |
| QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | NCT02383498 | Chordoma | Placebo GI-6301 Vaccine... Radiotherapy wGT3X-BT Actigr... | 18 Years - 100 Years | NantCell, Inc. | |
| Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer | NCT05152797 | Tumor Infiltrat... | Autologous tumo... | 18 Years - 75 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | NCT01369888 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Tumor Infiltrat... IL-15 | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | NCT03526185 | Metastatic Mela... | Tumor Infiltrat... Nivolumab and I... | 18 Years - | Yale University | |
| Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment | NCT05600933 | Solid Tumors Hematologic Mal... Gastrointestina... Liver Cancer Pancreatic Canc... Melanoma Pre-Malignancy Lung Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment | NCT05600933 | Solid Tumors Hematologic Mal... Gastrointestina... Liver Cancer Pancreatic Canc... Melanoma Pre-Malignancy Lung Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | NCT00338377 | Melanoma | Dendritic Cell ... Cyclophosphamid... Fludarabine T-Cells Interleukin-2 Mesna Intrathecal T-C... Intrathecal Int... | 12 Years - | M.D. Anderson Cancer Center | |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | NCT02360579 | Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma | NCT01946373 | Melanoma | Cyclophosphamid... Fludarabine T cells Interleukin-2 Dendritic cell ... | 18 Years - 74 Years | Karolinska University Hospital | |
| Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer | NCT05250336 | Breast Cancer Tumor Infiltrat... Programmed Cell... | Observational S... | 18 Years - 90 Years | Sanjay Gandhi Postgraduate Institute of Medical Sciences | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer | NCT05250336 | Breast Cancer Tumor Infiltrat... Programmed Cell... | Observational S... | 18 Years - 90 Years | Sanjay Gandhi Postgraduate Institute of Medical Sciences | |
| A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors | NCT05417750 | Tumor Infiltrat... Safety Advanced Solid ... Immunotherapy Efficacy Adverse Drug Ev... | TIL therapy | 18 Years - 75 Years | Shanghai Juncell Therapeutics | |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | NCT06060613 | Tumor Skin Metastatic Mela... Melanoma Lung Cancer Metastatic Lung... Non Small Cell ... Metastatic Non ... | OBX-115 | 18 Years - | Obsidian Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
